GC has filed a patent for a method to purify hemopexin and haptoglobin without the need for salt addition. The process involves titrating a plasma fraction sample to specific pH values and utilizing ion exchange chromatography to separate and purify the proteins individually. GlobalData’s report on GC gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GC, Personalized cancer vaccines was a key innovation area identified from patents. GC's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Purification method for hemopexin and haptoglobin
See Also:
A recently filed patent (Publication Number: US20240034749A1) outlines a method for purifying hemopexin and haptoglobin from a plasma fraction sample. The process involves steps such as dissolving the sample, performing strong and weak anion exchange chromatography, titrating the solution, and purifying the proteins separately. The method does not involve pre-treatment for pH titration before chromatography and does not include a precipitation step by salt addition. The resin used in the chromatography steps includes various options like Q Sepharose Fast Flow and Toyopearl DEAE. The purified hemopexin and haptoglobin can be mixed to form a pharmaceutical composition for preventing, ameliorating, or treating hemolysis mediated diseases like sickle cell disease and acute kidney injury.
Furthermore, the patent claims specify details such as the source of the plasma fraction sample, the dissolution buffer composition, and the elution buffer for haptoglobin. The method ensures the removal of impurities like aggregation factors and ceruloplasmin while adjusting the conductivity of the solution. The process involves sequential chromatography, buffer exchange, and concentration steps for both hemopexin and haptoglobin purification. The administration of a pharmaceutical composition containing the purified proteins is proposed for treating hemolysis mediated diseases in patients. Overall, the patent provides a detailed and systematic approach to purifying hemopexin and haptoglobin, highlighting its potential application in therapeutic interventions for various medical conditions related to hemolysis.
To know more about GlobalData’s detailed insights on GC, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
